B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fireman B.V. (NQ: IFRX )

1.863 -0.107 (-5.43%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fireman B.V.

< Previous 1 2 3 Next >
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
 
Via Benzinga
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading. 
Via Benzinga
Recap: InflaRx Q4 Earnings
InflaRx (NASDAQ:IFRX) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease
InflaRx N.V. (NASDAQ: IFRX) has  
Via Benzinga
Why InflaRx Shares Are Ripping Higher Thursday
InflaRx N.V. (NASDAQ:IFRX) 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition
InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small... 
Via Benzinga
InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). ... 
Via Benzinga
70 Biggest Movers From Friday
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results
Toward the end of trading Thursday, the Dow traded up 0.45% to 35,651.09 while the NASDAQ rose 1.21% to 15,420.51. The S&P also rose, gaining 0.83% to 4,589.40. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Nasdaq Rises Over 1%; Rafael Holdings Shares Slide
Midway through trading Thursday, the Dow traded up 0.40% to 35,631.75 while the NASDAQ rose 1.09% to 15,401.19. The S&P also rose, gaining 0.74% to 4,585.17. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
Mid-Morning Market Update: Markets Rise; Caterpillar Profit Beats Expectations
Following the market opening Thursday, the Dow traded up 0.53% to 35,678.96 while the NASDAQ rose 0.95% to 15,380.23. The S&P also rose, gaining 0.76% to 4,586.39. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
30 Stocks Moving in Thursday's Pre-Market Session
Gainers InflaRx N.V. (NASDAQ: IFRX) rose 47.9% to $4.23 in pre-market trading. Raymond James upgraded InflaRx from Outperform to Strong Buy and announced a $14 price target.... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group... 
Via Benzinga
InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial
The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the... 
Via Benzinga
Exposures COVID-19
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge
Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance
Following the market opening Tuesday, the Dow traded up 0.29% to 35,361.89 while the NASDAQ rose 0.31% to 15,068.75. The S&P also rose, gaining 0.39% to 4,503.81. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
18 Stocks Moving in Friday's Pre-Market Session
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.... 
Via Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers IronNet, Inc. (NYSE: IRNT) rose 89.7% to $31.61 in pre-market trading after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares rose 36.6% to $4.37 in pre-market... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients
InflaRx N.V. (NASDAQ: IFRX) has announced data from the first 10 evaluable patients in the ongoing Phase 2a open-label study with vilobelimab in Pyoderma... 
Via Benzinga
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.